Loading
NASDAQHealthcareMedical - Instruments & Supplies
Latest quote
$34.92
−$0.11 · -0.31%
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.
Previous close
$34.92
−$0.11 · -0.31%
Regular session · ET · Market data may be delayed.
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.
Day range
Current $34.92
52-week range
Current $34.92
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
87
Deep Value
Sentiment
66
Bullish
Risk
60
Elevated Risk
Momentum
57
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.
Day range
Current $34.92
52-week range
Current $34.92
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 103.12M USD | 86.67M USD | 64.99M USD | 45.84M USD | 24.14M USD |
| Cost of goods sold | 10.18M USD | 8.14M USD | 7.85M USD | 6.36M USD | 2.31M USD |
| Gross profit | 92.94M USD | 78.53M USD | 57.14M USD | 39.48M USD | 21.83M USD |
| Research and development | 5.07M USD | 5.7M USD | 4.13M USD | 3.37M USD | 558.7K USD |
| Selling, general, and administrative | 78.72M USD | 76.56M USD | 56.99M USD | 45.98M USD | 28.05M USD |
| Operating expenses | 83.79M USD | 85.25M USD | 61.35M USD | 52M USD | 29.21M USD |
| Interest income | 3.67K USD | 21.98K USD | — | 284.75K USD | — |
| Interest expense | 6.76M USD | 3.13M USD | 475.78K USD | 284.75K USD | 711 USD |
| Depreciation and amortization | 2.66M USD | 4.92M USD | 3.68M USD | 2.37M USD | 771.93K USD |
| Operating income | 9.15M USD | −6.72M USD | −4.22M USD | −12.52M USD | −7.38M USD |
| Net income | −37.56M USD | −9.66M USD | −4.3M USD | −7.94M USD | −7.92M USD |
Company facts updated Sep 13, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$35.00
0.23% upsideLimited analyst sample: 3 ratings. Interpret the distribution with caution.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
DividendUpcoming | Jul 29, 2027 | $33.00Irregular | — | — |
Ex-dividend Jul 29, 2027
$33.00
Irregular
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI5.04M0.00%2.3T USD0.03%$376.31+0.82%
iShares Russell 2000 ETFIWM2.92M0.00%77.55B USD0.19%$288.89+0.41%
Vanguard Extended Market ETFVXF1.45M0.00%93.7B USD0.05%$237.76+0.68%
iShares Russell 2000 Growth ETFIWO1.11M0.01%14.32B USD0.24%$367.63+0.54%
Fidelity Enhanced Small Cap ETFFESM876.59K0.01%6.49B USD0.28%$46.36+0.78%
Vanguard Russell 2000 ETFVTWO649.54K0.00%17.4B USD0.06%$116.76+0.36%
iShares Micro-Cap ETFIWC405.37K0.03%1.44B USD0.60%$190.84+0.39%
Avantis U.S. Small Cap Equity ETFAVSC212.35K0.01%3.09B USD0.25%$71.48+0.53%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCAvantis U.S. Small Cap Equity ETFAVSCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
